poisar

Stock

Vanda Pharmaceuticals Inc. VNDA

$5.43+2.07%

Overview

VNDA market data

Price History

VNDA price chart · 1M
O
5.35
H
5.49
L
5.35
C
5.43
Vol
42,050.00
Source
US equities market feed
Observed
Aug 25, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$5.35
Previous Close
$5.32
Day High
$5.49
Day Low
$5.35
52 Week High
$9.94
52 Week Low
$4.48
7 Day Return
-0.37%
30 Day Return
+3.82%
90 Day Return
-16.01%
1 Year Return
-31.35%
Daily Notional Volume
$228.3K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$3.74
Diluted earnings per share over the trailing twelve months.
Beta
0.66
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-110.0%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$4.27 – $9.94
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $304.3M · P/B 1.59 · P/S 1.40.

Company News

7 captured
Vanda Pharmaceuticals Receives EMA Orphan Designation For Imsidolimab For The Treatment Of Generalized Pustular PsoriasisBenzinga · Aug 24, 2026, 1:28 PM
B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12Benzinga · Aug 10, 2026, 5:17 PM
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20Benzinga · Aug 10, 2026, 10:23 AM
Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M EstimateBenzinga · Aug 5, 2026, 8:06 PM
Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M EstBenzinga · Aug 5, 2026, 8:05 PM
Vanda Pharmaceuticals Announces European Medicines Agency Adopts Positive Opinion For Orphan Drug Designation Of Imsidolimab For Generalized Pustular PsoriasisBenzinga · Jul 16, 2026, 8:32 PM
Vanda Pharma Says FDA Grants Rare Pediatric Disease Designation To VCA-894A For Treatment Of Charcot-Marie-Tooth Disease, Axonal, Type 2SBenzinga · Jul 7, 2026, 8:40 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock